相关实验视频
Updated: Sep 13, 2025

05:56
A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
Published on: February 20, 2021
2.2K
在败血症中使用葡萄糖类-1受体激活剂的潜力
Noel Tomy1, Benjamin Shwartzman, William H Frishman
1From the Department of Medicine, New York Medical College, Valhalla, NY.
Cardiology in review
|August 1, 2025
概括
葡萄糖类-1 (GLP-1) 激动剂在预防败血症并发症方面表现有前途. 这些药物减少了炎症和器官损伤,有可能改善风险人群的生存率.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 关键护理医学 关键护理医学
背景情况:
- 败血症是一种全球性卫生危机,导致大量死亡.
- 葡萄糖类-1 (GLP-1) 激动剂已成为2型糖尿病和肥胖症的治疗方法.
- 新兴研究表明GLP-1激动剂可能会对败血症产生保护作用.
研究的目的:
- 审查GLP-1激动剂在减轻败血症方面的潜力.
- 探索GLP-1激动剂可以预防败血症相关并发症的机制.
- 评估临床前和临床证据支持GLP-1激动剂在败血症.
主要方法:
- 对毒症动物模型的临床前研究的审查.
- 对GLP-1激动剂使用和感染相关结果的临床数据的分析.
- 检查GLP-1激动剂对败血症相关的分子和细胞效应.
主要成果:
- 临床前研究表明GLP-1激动剂可以减少炎症,氧化应激和线粒体功能障碍.
- 动物模型显示,GLP-1激动剂治疗改善了器官保护和存活率.
- 临床数据表明,可能会减少与感染有关的并发症和死亡率.
结论:
- GLP-1激动剂表现出抗炎,心脏保护和潜在的神经保护性质.
- 这些药物可以保持内皮完整性和细胞能量恒温.
- GLP-1激动剂是高风险人群中败血症预防的有希望的辅助策略.
相关概念视频
Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
Hypoglycemia and Glucagon
338
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
338
GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K

